RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic lymphocytic leukemia (CLL) cells and are effective therapies for this disease. Biological therapies, such as Imprime PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose), may stimulate the immune system in different ways and help monoclonal antibodies kill CLL cells. Giving PGG beta-glucan together with alemtuzumab and rituximab could make therapy with monoclonal antibodies, such as alemtuzumab and rituximab, more effective.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PGG beta-glucan when given together with alemtuzumab and rituximab and to see how well it works in treating patients with earlier stage high-risk chronic lymphocytic leukemia.

开始日期2011-01-01

申办/合作机构

Mayo Clinic

[+1]

100 项与 PGG-Glucan (Alpha-Beta Technology, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 PGG-Glucan (Alpha-Beta Technology, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 PGG-Glucan (Alpha-Beta Technology, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 PGG-Glucan (Alpha-Beta Technology, Inc.) 相关的文献（医药）

2022-03-04·Natural Product Research3区 · 化学

Insight into the α-glucosidase-inhibiting mechanism of β-PGG, a commonly occurring polyphenol in diets

3区 · 化学

Article

作者: Zhang, Xiao-Yue ; Zheng, Hang-Hang ; Huang, Cheng-Di ; Zhang, Qiang ; Liu, Da-Zhi ; Gao, Jin-Ming

1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranose (β-PGG) is a compound commonly available in vegetables and fruits. It exhibited potential inhibition of α-glucosidase and hypoglycemic effect in vivo. This study explored its dynamics properties inhibiting α-glucosidase by Lineweaver - Burk plots, spectral analysis, docking analysis, and molecular dynamics simulations. β-PGG showed a mix-type inhibition when it was interacting with α-glucosidase. The fluorescence quenching indicated that the PGG-glucosidase complex formed in a spontaneous exothermic process and was driven by enthalpy. The synchronous fluorescence and ECD spectra indicate that β-PGG induced and changed the enzyme conformation in the complex formation. Docking results revealed multiple hydrogen bonds between the phenols and the amino acid residues. Further dynamic simulations indicated that the residues Asp345, Phe153, Arg435, Glu300, Pro305, and Phe296 played a more critical role in the interactions between β-PGG and α-glucosidase.

2021-11-01·European Journal of Pharmacology3区 · 医学

Reversal of elastase-induced abdominal aortic aneurysm following the delivery of nanoparticle-based pentagalloyl glucose (PGG) is associated with reduced inflammatory and immune markers

3区 · 医学

Article

作者: Rice, Charles D ; Dhital, Saphala ; Vyavahare, Naren R

OBJECTIVEAn Abdominal aortic aneurysm (AAA), a deadly disease in elderly population, is featured by expansion of aortic diameter, degradation and weakening of vasculature. Its common and significant characteristics are disarray and inflammation in vasculature. We tested the hypothesis that the reversal of abdominal aortic aneurysm by pentagalloyl glucose-loaded nanoparticles (PGG-NPs) therapy that targets degraded elastin suppresses inflammatory and immune markers to ameliorate the pathophysiology of the disease in advance stage aneurysm in a porcine pancreatic elastase (PPE)-induced mouse model of AAA.METHODS AND RESULTSAfter induction of aneurysm in pathogen-free C57BL/6 male mice by applying PPE peri-adventitially to the abdominal aorta, once a week for two doses of intravenous injections of pentagalloyl glucose-loaded nanoparticles (PGG-NPs) conjugated with elastin targeted antibody were used to reverse the aneurysms. We showed that PGG-NPs therapy could suppress infiltration of macrophages, CD8 and CD4 subsets of T cells, matrix metalloproteinases (MMPs), inflammatory cytokines interferon (IFN-γ) and interleukin (IL)-6 at the local and systemic level. Moreover, such PGG-NPs therapy increases the induction of anti-inflammatory cytokines IL-13, IL-27 and IL-10 at the local and systemic level. The therapy also led to remodeling of elastic lamina at the aneurysm site.CONCLUSIONNanoparticles-loaded pentagalloyl glucose therapy can be an effective treatment option against advanced stage aneurysms to reverse the disease by ameliorating inflammation and restoring arterial homeostasis.

2020-09-01·International Journal of Biological Macromolecules1区 · 化学

Structure-activity relationship analysis of Panax ginseng glycoproteins with cytoprotective effects using LC-MS/MS and bioinformatics

1区 · 化学

Article

作者: Jiang, Ruizhi ; Qiu, Zhidong ; Chen, Yinghong ; Luo, Haoming ; Fang, Xiaoxue ; Zhu, Difu ; Shan, Mengyao

Panax ginseng glycoproteins (PGG) has been shown biological activity, but researches in this field are rarely reported. In this paper, PGG were prepared by reflux and then purified with macroporous resin column. Further separation and purification of PGG using high performance liquid chromatography (HPLC) and two major components (PGG-1, PGG-2) were obtained. The molecular weights were calculated by gel permeation chromatography (GPC), and the results are 1.5 KDa and 8.2 KDa respectively. The MTT assay was used to study the cytoprotective effects of PGG, the results exhibited that PGG had significant effect (P < 0.01), and showed an obvious dose-effect relationship. Anti-apoptosis experiment results showed that PGG and PGG-2 can inhibit Aβ-induced apoptosis in SH-SY5Y cells (P < 0.05), and PGG-2 displayed better activity. The structures of N- and O-glycan were determined by combination of LC-MS/MS and methylation analysis. The computed parameters of PGG determined by MS including the theoretical isoelectric point (pI), instability index, aliphatic index and grand average of hydropathicity (GRAVY) were summarized systematically. The distinct differences between two parts would affect the behavior of PGG in vivo. The results of activity test and bioinformatics analysis would guide the study of PGG in pharmacokinetics and mechanism.

100 项与 PGG-Glucan (Alpha-Beta Technology, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结直肠癌	临床3期	-	Alpha-Beta Technology, Inc.	-
结直肠癌	临床3期	-	Mayo Clinic	-
难治性慢性淋巴细胞白血病	药物发现	美国	National Cancer Institute	2011-01-01